




Edition: BP 2025 (Ph. Eur. 11.6 update)

## Tiapride Hydrochloride

### [General Notices](#)

(Ph. Eur. monograph 1575)



C<sub>15</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>4</sub>S 364.9 51012-33-0

### Action and use

Dopamine receptor antagonist; neuroleptic.

Ph Eur

## DEFINITION

*N*-[2-(Diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)benzamide hydrochloride.

### Content

98.5 per cent to 101.0 per cent (dried substance).

## CHARACTERS

### Appearance

White or almost white, crystalline powder.

### Solubility

Very soluble in water, soluble in methanol, slightly soluble in anhydrous ethanol.

## IDENTIFICATION

A. Infrared absorption spectrophotometry ([2.2.24](#)).

Comparison [tiapride hydrochloride CRS](#).

B. Solution S (see Tests) gives reaction (a) of chlorides ([2.3.1](#)).

## TESTS

### Solution S

Dissolve 2.5 g in [carbon dioxide-free water R](#) and dilute to 50.0 mL with the same solvent.

### Appearance of solution

Solution S is clear ([2.2.1](#)) and its absorbance ([2.2.25](#)) at 450 nm is not greater than 0.030.

### pH ([2.2.3](#))

4.0 to 6.0 for solution S.

### Impurity C

Thin-layer chromatography ([2.2.27](#)).

*Test solution* Dissolve 0.400 g of the substance to be examined in [methanol R](#) and dilute to 10 mL with the same solvent.

*Reference solution* Dissolve 20.0 mg of [metoclopramide impurity E CRS](#) (impurity C) in [methanol R](#) and dilute to 50 mL with the same solvent. Dilute 2.0 mL of the solution to 20 mL with [methanol R](#).

*Plate* [TLC silica gel F<sub>254</sub> plate R](#).

*Mobile phase* [concentrated ammonia R](#), [dioxan R](#), [methanol R](#), [methylene chloride R](#) (2:10:14:90 V/V/V/V).

*Application* 10 µL.

*Development* Over 4/5 of the plate.

*Drying* In air.

*Detection* Spray with a 2 g/L solution of [ninhydrin R](#) in [butanol R](#) and heat at 100 °C for 15 min.

*Retardation factors* Impurity C = about 0.1; tiapride = about 0.6.

*Limit:*

— *impurity C*: any spot due to impurity C is not more intense than the corresponding spot in the chromatogram obtained with the reference solution (0.1 per cent).

### Related substances

Liquid chromatography ([2.2.29](#)).

*Test solution* Dissolve 0.100 g of the substance to be examined in the mobile phase and dilute to 100.0 mL with the mobile phase.

*Reference solution (a)* Dilute 1.0 mL of the test solution to 10.0 mL with the mobile phase. Dilute 1.0 mL of this solution to 100.0 mL with the mobile phase.

*Reference solution (b)* Dissolve 5.0 mg of [tiapride hydrochloride CRS](#) and 5.0 mg of [tiapride N-oxide CRS](#) (impurity D) in the mobile phase and dilute to 100.0 mL with the mobile phase.

*Column:*

— *size*:  $l = 0.25$  m,  $\varnothing = 4.6$  mm;

— *stationary phase*: [base-deactivated end-capped octylsilyl silica gel for chromatography R](#) (5 µm);

— *temperature*: 40 °C.

**Mobile phase** Dissolve 5.44 g of [potassium dihydrogen phosphate R](#) and 0.08 g of [sodium octanesulfonate R](#) in 780 mL of [water R](#), adjust to pH 2.7 with [phosphoric acid R](#) and dilute to 800 mL with [water R](#); add 150 mL of [methanol R](#) and 50 mL of [acetonitrile R](#) and mix.

**Flow rate** 1.5 mL/min.

**Detection** Spectrophotometer at 240 nm.

**Injection** 10 µL.

**Run time** 3 times the retention time of tiapride.

**Identification of impurities** Use the chromatogram obtained with reference solution (b) to identify the peak due to impurity D.

**Relative retention** With reference to tiapride (retention time = about 7 min): impurity D = about 1.2.

**System suitability** Reference solution (b):

- **resolution**: minimum 4.0 between the peaks due to tiapride and impurity D.

**Calculation of percentage contents:**

- for each impurity, use the concentration of tiapride hydrochloride in reference solution (a).

**Limits:**

- **unspecified impurities**: for each impurity, maximum 0.10 per cent;
- **total**: maximum 0.2 per cent;
- **reporting threshold**: 0.05 per cent.

### **Loss on drying (2.2.32)**

Maximum 0.5 per cent, determined on 1.000 g by drying in an oven at 105 °C.

### **Sulfated ash (2.4.14)**

Maximum 0.1 per cent, determined on 1.0 g.

## **ASSAY**


Dissolve 0.300 g in 20 mL of [anhydrous acetic acid R](#). Add 20 mL of [acetic anhydride R](#). Titrate with [0.1 M perchloric acid](#), determining the end-point potentiometrically ([2.2.20](#)).

1 mL of [0.1 M perchloric acid](#) is equivalent to 36.49 mg of C<sub>15</sub>H<sub>25</sub>ClN<sub>2</sub>O<sub>4</sub>S.


## **IMPURITIES**

**Specified impurities** C.


*Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph [Substances for pharmaceutical use \(2034\)](#). It is therefore not necessary to identify these impurities for demonstration of compliance. See also [5.10. Control of impurities in substances for pharmaceutical use](#))* A, B, D.




A. methyl 2-methoxy-5-(methylsulfonyl)benzoate,



B. 2-methoxy-5-(methylsulfonyl)benzoic acid,



C. *N,N*-diethylethane-1,2-diamine,



D. *N*-[2-(diethyloxidoaminol)ethyl]-2-methoxy-5-(methylsulfonyl)benzamide (tiapride *N*-oxide).

---

Ph Eur